NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$87.38 -1.76 (-1.97 %)
(As of 04/18/2019 04:00 PM ET)
Previous Close$89.14
Today's Range$86.51 - $90.3430
52-Week Range$64.50 - $133.74
Volume1.21 million shs
Average Volume1.03 million shs
Market Capitalization$2.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.80 million
Book Value$0.64 per share

Profitability

Net Income$-309,240,000.00
Net Margins-172.39%

Miscellaneous

Employees483
Market Cap$2.59 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings results on Thursday, February, 28th. The biopharmaceutical company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.42) by $0.55. The biopharmaceutical company had revenue of $53.30 million for the quarter, compared to the consensus estimate of $52.53 million. Intercept Pharmaceuticals had a negative return on equity of 592.58% and a negative net margin of 172.39%. The firm's revenue for the quarter was up 41.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($4.43) EPS. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

21 brokers have issued twelve-month target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $68.00 to $251.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $146.40 in the next year. This suggests a possible upside of 67.5% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)
  • 2. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC. Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. While we are pleased with the approval of Ocaliva, the company’s dependence on a single product for growth has its risks. Any negative news related to Ocaliva would adversely impact Intercept and its growth prospects. The lack of other candidates in the pipeline is concerning. Nevertheless, the company is looking to expand the drug’s label in the promising NASH and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Shares have outperformed the industry in the last six months." (2/15/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News headlines about ICPT stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Biogen (BIIB) and Regeneron Pharmaceuticals (REGN).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. David Ford, Chief HR Officer (Age 50)
  • Dr. David Shapiro, Chief Medical Officer (Age 65)

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.38%), Private Capital Advisors Inc. (0.03%), Wedbush Securities Inc. (0.02%) and Virtu Financial LLC (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Rachel Mcminn, Richard J Kim, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski, Paolo Fundaro, SPA Genextra and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc., Peregrine Capital Management LLC and Wedbush Securities Inc.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $87.38.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.59 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  905 (Vote Outperform)
Underperform Votes:  523 (Vote Underperform)
Total Votes:  1,428
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel